Surviving the Blockbuster Syndrome

Abstract
New technologies have sent drug company R&D costs soaring, but with no corresponding rise as yet in the number of new drugs. Executives are talking about mergers, reorganization, and other ways to kick-start their production engines.

This publication has 0 references indexed in Scilit: